E. Lampka

CHOP-21 for unfavorable Hodgkin’s lymphoma. An exploratory study

J. Walewski, E. Kraszewska, E. Lampka, 2010, Medical oncology.

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2022, Scientific Reports.

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

K. Sułek, R. Dziadziuszko, A. Nagler, 2002, Bone Marrow Transplantation.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

M. Kersten, A. Hagenbeek, G. Salles, 2009, The Lancet. Oncology.

Combination chemotherapy for Hodgkin's lymphoma during pregnancy: Favorable outcome for mother and child

A. Semczuk, D. Sagan, E. Lampka, 2010, The journal of obstetrics and gynaecology research.

CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma

J. Walewski, E. Kraszewska, J. Romejko-Jarosińska, 2000, Medical oncology.

Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study

M. Rosińska, A. Borowiec, A. Cieszanowski, 2023, PloS one.